EPISODE · Apr 24, 2026 · 4 MIN
Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus
from OncoTalks | Oncology Insights at Your Fingertips · host Ontada Learn
Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
What this episode covers
Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
NOW PLAYING
Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m